BRAF and hepatoblastoma: The cytotoxic activity of DHIE has been studied on different cancer cell lines, such as leukemia (CEM/ADR5000), breast cancer (MDA-MB-231-pcDNA, MDA-MB-231-BCRP), colorectal cancer (HCT116p53+/+, HCTp53−/−), glioblastoma (U87MG), hepatoblastoma (HepG2), melanoma (BRAF-V600E, MAMEL-80A, SK-MEL28, BRAF-V600E-A2058, BRAF wildtype, MV3, SK-MEL505), rat adenocarcinoma (CC531), mouse melanoma (B1-F1 and B16-F10); the IC50 values varied from 4.3 to 22.4 μg/mL.